Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 28, 2020; 26(12): 1231-1241
Published online Mar 28, 2020. doi: 10.3748/wjg.v26.i12.1231
Venous thromboembolism in inflammatory bowel disease
Kimberly Cheng, Adam S Faye
Kimberly Cheng, Department of Medicine, NewYork-Presbyterian Columbia University Medical Center, New York, NY 10032, United States
Adam S Faye, Department of Medicine, Columbia University Medical Center, NewYork-Presbyterian Hospital, New York, NY 10032, United States
Author contributions: Cheng K and Faye AS performed the literature review; Cheng K and Faye AS drafted the manuscript; Cheng K and Faye AS performed critical revision of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Adam S Faye, MD, Postdoctoral Fellow, Research Fellow, Department of Medicine, Columbia University Medical Center, NewYork-Presbyterian Hospital, 622 West 168th St., P&S-3, New York, NY 10032, United States.
Received: December 17, 2019
Peer-review started: December 17, 2019
First decision: January 7, 2020
Revised: March 4, 2020
Accepted: March 9, 2020
Article in press: March 9, 2020
Published online: March 28, 2020
Core Tip

Core tip: Venous thromboembolism is a known complication in patients with inflammatory bowel disease that is associated with significant cost, morbidity, and mortality. Certain patient specific risk factors, such as age, pregnancy, active disease, colorectal surgery, and the use of corticosteroids and tofacitinib can increase venous thromboembolism risk. We herein explore these patient specific risk factors, consider the utility of post-discharge venous thromboembolism prophylaxis, and discuss mechanisms to improve pharmacologic prophylaxis rates among hospitalized inflammatory bowel disease patients.